1. Home
  2. ACET

as 05-17-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Founded: 1947 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 119.1M IPO Year: N/A
Target Price: $13.86 AVG Volume (30 days): 1.4M
Analyst Decision: Buy Number of Analysts: 8
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.94 EPS Growth: N/A
52 Week Low/High: $1.10 - $6.65 Next Earning Date: 05-14-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks:

Stock Insider Trading Activity of Adicet Bio Inc. (ACET)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
GORDON CARL L ACET Director10% Owner Jan 25 '24 Buy $2.40 1,841,100 $4,418,640.00 7,526,359 SEC Form 4
GORDON CARL L ACET Director10% Owner Jan 25 '24 Buy $2.40 242,200 $581,280.00 990,254 SEC Form 4
GORDON CARL L ACET Director10% Owner Jan 25 '24 Buy $2.40 1,041,700 $2,500,080.00 1,255,985 SEC Form 4